Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inbar Levi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Functional Biomaterials|March 27, 2026
Micro- and Nano-Structuring of Hydroxyapatite-MMT-Loaded Hydrogels for Bone Regeneration ApplicationsInbar Eshkol-Yogev, Tom Hanoon Kogan, Inbar Levi, et al.
Oncotarget|June 17, 2015
Characterization of tumor infiltrating natural killer cell subsetInbar Levi, Hagai Amsalem, Aviram Nissan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2012
Cells exposed to sublethal oxidative stress selectively attract monocytes/macrophages via scavenger receptors and MyD88-mediated signalingAnat Geiger-Maor, Inbar Levi, Sharona Even-Ram, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2021
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunityDavid Hagin, Tal Freund, Michal Navon, et al.
Open Forum Infectious Diseases|August 4, 2023
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort StudyLuba Tau, David Hagin, Tal Freund, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|January 12, 2026
Community-onset symptomatic urinary tract infections (SUTI) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: independent predictors and comparative effectiveness of oral agentsShani Zilberman-Itskovich, Majdi Masarwi, Eyal Levy, et al.
Open Forum Infectious Diseases|March 31, 2022
SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical CenterLuba Tau, Dan Turner, Amos Adler, et al.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
EMBO Molecular Medicine|January 11, 2017
Sequence variation in <i>PPP1R13L</i> results in a novel form of cardio-cutaneous syndromeTzipora C Falik-Zaccai, Yiftah Barsheshet, Hanna Mandel, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Functional Biomaterials|March 27, 2026
Micro- and Nano-Structuring of Hydroxyapatite-MMT-Loaded Hydrogels for Bone Regeneration ApplicationsInbar Eshkol-Yogev, Tom Hanoon Kogan, Inbar Levi, et al.
Oncotarget|June 17, 2015
Characterization of tumor infiltrating natural killer cell subsetInbar Levi, Hagai Amsalem, Aviram Nissan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2012
Cells exposed to sublethal oxidative stress selectively attract monocytes/macrophages via scavenger receptors and MyD88-mediated signalingAnat Geiger-Maor, Inbar Levi, Sharona Even-Ram, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2021
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunityDavid Hagin, Tal Freund, Michal Navon, et al.
Open Forum Infectious Diseases|August 4, 2023
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort StudyLuba Tau, David Hagin, Tal Freund, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|January 12, 2026
Community-onset symptomatic urinary tract infections (SUTI) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: independent predictors and comparative effectiveness of oral agentsShani Zilberman-Itskovich, Majdi Masarwi, Eyal Levy, et al.
Open Forum Infectious Diseases|March 31, 2022
SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical CenterLuba Tau, Dan Turner, Amos Adler, et al.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
EMBO Molecular Medicine|January 11, 2017
Sequence variation in <i>PPP1R13L</i> results in a novel form of cardio-cutaneous syndromeTzipora C Falik-Zaccai, Yiftah Barsheshet, Hanna Mandel, et al.
Pageof 2